Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its investigational allosteric MEK1/2 inhibitor designed to treat Familial Adenomatous Polyposis/FAP.
FAP is a rare, life-altering hereditary condition affecting over 50,000 people in the US and EU5. It is driven by inactivating mutations in the APC gene, which typically result in a near-100% lifetime risk of colorectal cancer. Currently, no medical therapies are approved, forcing patients to undergo frequent endoscopic removals and major surgeries, such as colectomies, starting in their early 20s.
The TUPELO trial data demonstrated that REC-4881 achieved both rapid and durable clinical activity. The study revealed that 87% of untreated individuals experience a progressive increase in polyp burden, with only 3% showing any modest decrease. The safety profile of REC-4881 remained consistent with the MEK1/2 inhibitor class; most treatment-related adverse events were mild (Grade 1 or 2), such as acneiform dermatitis or elevated blood CPK. While Grade 3 events occurred in 15.8% of the safety population, no Grade 4 or 5 events have been reported to date.
This trial represents a major milestone for the Recursion OS, as REC-4881 was identified through AI-driven phenotypic screening that linked MEK1/2 inhibition to the rescue of $APC$ loss-of-function. The company originally in-licensed the molecule from Takeda, where it had previously been studied for solid tumors. Recursion now plans to expand the study population to include patients as young as 18 and intends to engage with the FDA in H1 2026 to define a potential registration pathway for the drug.
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) operates as a clinical-stage biotechnology company that decodes biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the US.
While we acknowledge the potential of RXRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RXRX and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center